These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 35520101)

  • 1. The prognostic impact of bone metastasis in patients with metastatic urothelial carcinoma treated with first-line platinum-based chemotherapy.
    Alqaisi HA; Stecca C; Veitch ZW; Riromar J; Kaiser J; Fallah-Rad N; Jiang DM; North S; Samnani S; Alimohamed N; Sridhar SS
    Ther Adv Med Oncol; 2022; 14():17588359221094879. PubMed ID: 35520101
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Real-World Data Study to Evaluate Treatment Patterns, Clinical Characteristics and Survival Outcomes for First- and Second-Line Treatment in Locally Advanced and Metastatic Urothelial Cancer Patients in Germany.
    Niegisch G; Gerullis H; Lin SW; Pavlova J; Gondos A; Rudolph A; Haas G; Hennies N; Kramer MW
    J Cancer; 2018; 9(8):1337-1348. PubMed ID: 29721042
    [No Abstract]   [Full Text] [Related]  

  • 3. Disease control with prior platinum-based chemotherapy is prognostic for survival in patients with metastatic urothelial cancer treated with atezolizumab in real-world practice.
    Mencinger M; Mangaroski D; Bokal U
    Radiol Oncol; 2021 May; 55(4):491-498. PubMed ID: 33939898
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of Bone Metastases in Patients Receiving Immunotherapy for Pre-Treated Urothelial Carcinoma: The Multicentre, Retrospective Meet-URO-1 Bone Study.
    Raggi D; Giannatempo P; Marandino L; Pierantoni F; Maruzzo M; Lipari H; Banna GL; De Giorgi U; Casadei C; Naglieri E; Buti S; Bersanelli M; Stellato M; Santini D; Vignani F; Roviello G; Veccia A; Caffo O; Losanno T; Calabrò F; Mucciarini C; Pignata S; Necchi A; Maio MD;
    Clin Genitourin Cancer; 2022 Apr; 20(2):155-164. PubMed ID: 35000876
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Multi-institutional, Retrospective Analysis of Patients with Metastatic Renal Cell Carcinoma to Bone Treated with Combination Ipilimumab and Nivolumab.
    Desai K; Brown L; Wei W; Tucker M; Kao C; Kinsey E; Rini B; Beckermann K; Zhang T; Ornstein MC
    Target Oncol; 2021 Sep; 16(5):633-642. PubMed ID: 34379283
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical Outcomes of Patients With Metastatic Urothelial Carcinoma After Progression to Immune Checkpoint Inhibitors: A Retrospective Analysis by the Meet-Uro Group (Meet-URO 1 Study).
    Bersanelli M; Buti S; Cortellini A; Bandini M; Banna GL; Pederzoli F; Farè E; Raggi D; Giannatempo P; De Giorgi U; Basso U; Losanno T; Santini D; Mucciarini C; Tucci M; Tambaro R; Farnesi A; Caffo O; Veccia A; Naglieri E; Briganti A; Procopio G; Pignata S; Necchi A
    Clin Med Insights Oncol; 2021; 15():11795549211021667. PubMed ID: 34290538
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of Platinum Rechallenge in Metastatic Urothelial Carcinoma After Previous Platinum-Based Chemotherapy for Metastatic Disease.
    Wong RL; Ferris LA; Do OA; Holt SK; Ramos JD; Crabb SJ; Sternberg CN; Bellmunt J; Ladoire S; De Giorgi U; Harshman LC; Vaishampayan UN; Necchi A; Srinivas S; Pal SK; Niegisch G; Dorff TB; Galsky MD; Yu EY
    Oncologist; 2021 Dec; 26(12):1026-1034. PubMed ID: 34355457
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-World Evidence of Tumor and Patient Characteristics and Survival with Avelumab Maintenance after Chemotherapy for Advanced and Metastatic Urothelial Carcinoma.
    Banek S; Wenzel M; Lauer B; Le QC; Hoeh B; Koll F; Cano Garcia C; Humke C; Köllermann J; Chun FKH; Kosiba M; Kluth LA
    Urol Int; 2024; 108(4):285-291. PubMed ID: 38447555
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cisplatin- Versus Non-Cisplatin-based First-Line Chemotherapy for Advanced Urothelial Carcinoma Previously Treated With Perioperative Cisplatin.
    Locke JA; Pond GR; Sonpavde G; Necchi A; Giannatempo P; Paluri RK; Niegisch G; Albers P; Buonerba C; Di Lorenzo G; Vaishampayan UN; North SA; Agarwal N; Hussain SA; Pal S; Eigl BJ
    Clin Genitourin Cancer; 2016 Aug; 14(4):331-40. PubMed ID: 26589729
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Baseline Modified Glasgow Prognostic Score Associated with Survival in Metastatic Urothelial Carcinoma Treated with Immune Checkpoint Inhibitors.
    Brown JT; Liu Y; Shabto JM; Martini DJ; Ravindranathan D; Hitron EE; Russler GA; Caulfield S; Yantorni LB; Joshi SS; Kissick H; Ogan K; Harris WB; Carthon BC; Kucuk O; Master VA; Bilen MA
    Oncologist; 2021 May; 26(5):397-405. PubMed ID: 33634507
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression Levels of DNA Damage Repair Proteins Are Associated With Overall Survival in Platinum-Treated Advanced Urothelial Carcinoma.
    Mullane SA; Werner L; Guancial EA; Lis RT; Stack EC; Loda M; Kantoff PW; Choueiri TK; Rosenberg J; Bellmunt J
    Clin Genitourin Cancer; 2016 Aug; 14(4):352-9. PubMed ID: 26778300
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Phase II Study of Weekly Docetaxel as Second-Line Chemotherapy in Patients With Metastatic Urothelial Carcinoma.
    Kim YS; Lee SI; Park SH; Park S; Hwang IG; Lee SC; Sun JM; Lee J; Lim HY
    Clin Genitourin Cancer; 2016 Feb; 14(1):76-81. PubMed ID: 26454620
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-world analysis of first-line afatinib in patients with
    Kim J; Jang TW; Choi CM; Kim MH; Lee SY; Park CK; Chang YS; Lee KY; Kim SJ; Yang SH; Ryu JS; Lee JE; Lee SY; Park CK; Lee SH; Jang SH; Yoon SH
    Transl Lung Cancer Res; 2023 Jun; 12(6):1197-1209. PubMed ID: 37425421
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bone targeting agents, but not radiation therapy, improves survival in patients with bone metastases from advanced urothelial carcinoma receiving pembrolizumab: results from the ARON-2 study.
    Santoni M; Massari F; Takeshita H; Tapia JC; Dionese M; Pichler R; Rizzo M; Lam ET; Grande E; Kemp R; Molina-Cerrillo J; Calabrò F; Tural D; Küronya Z; Kucharz J; Fiala O; Seront E; Kopp RM; Abahssain H; Kopecky J; Martignetti A; Kanesvaran R; Zakopoulou R; Ansari J; Landmesser J; Mollica V; Porta C; Bellmunt J; Salah S; Santini D
    Clin Exp Med; 2023 Dec; 23(8):5413-5422. PubMed ID: 37917218
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic Value of Baseline Neutrophil-to-Lymphocyte Ratio in Metastatic Urothelial Carcinoma Patients Treated With First-line Chemotherapy: A Large Multicenter Study.
    Auvray M; Elaidi R; Ozguroglu M; Guven S; Gauthier H; Culine S; Caty A; Dujardin C; Auclin E; Thibaut C; Combe P; Tartour E; Oudard S
    Clin Genitourin Cancer; 2017 Jun; 15(3):e469-e476. PubMed ID: 27964892
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sex hormones influence survival of patients with metastatic urothelial carcinoma undergoing immune checkpoint therapy.
    Lindner AK; Lackner F; Tymoszuk P; Barth DA; Seeber A; Kocher F; Toth B; Hochleitner M; Pichler M; Pichler R
    Biol Sex Differ; 2023 Jun; 14(1):38. PubMed ID: 37277835
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vinflunine treatment in patients with metastatic urothelial cancer: A Nordic retrospective multicenter analysis.
    Holmsten K; Dohn L; Jensen NV; Shah CH; Jäderling F; Pappot H; Ullén A
    Oncol Lett; 2016 Aug; 12(2):1293-1300. PubMed ID: 27446429
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and Safety of nab-Paclitaxel vs Paclitaxel on Survival in Patients With Platinum-Refractory Metastatic Urothelial Cancer: The Canadian Cancer Trials Group BL.12 Randomized Clinical Trial.
    Sridhar SS; Blais N; Tran B; Reaume MN; North SA; Stockler MR; Chi KN; Fleshner NE; Liu G; Robinson JW; Mukherjee SD; Rahim Y; Winquist E; Booth CM; Nguyen NT; Beardsley EK; Alimohamed NS; McDonald GT; Ding K; Parulekar WR
    JAMA Oncol; 2020 Nov; 6(11):1751-1758. PubMed ID: 32940628
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Survival Prediction by Baseline Systemic Immune-inflammation Index (SII) and its Changes During First-line Platinum-based Treatment in a Caucasian Population of Patients With Metastatic Urothelial Carcinoma (MUC).
    Palacka P; Slopovsky J; Obertova J; Chovanec M; Rejlekova K; Sycova-Mila Z; Kollarik B; Mardiak J; Mego M
    Anticancer Res; 2021 Nov; 41(11):5749-5759. PubMed ID: 34732448
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic Impact of Bone Metastasis in Patients With Metastatic Urothelial Carcinoma Treated With Durvalumab With or Without Tremelimumab in the DANUBE Study.
    Stecca C; Abdeljalil O; Sridhar SS
    Clin Genitourin Cancer; 2024 Dec; 22(6):102215. PubMed ID: 39353213
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.